Pip/Tazo: Back in the cards!

August 2012 IN THIS ISSUE

MALDI-TOF Draws a Crowd

New VITEK® 2 GN AST cards available October 1

GN AST Cards Menu

Etest® Customer Article

World Sepsis Day is September 13

Coming Soon: BacT/ALERT® 3D B.40 Firmware Upgrade

Events Calendar

bioMérieux

Newsletter

Pip/Tazo: Back in the cards! Dealingyouanewwinninghandforsusceptibilitytesting

bioMérieux’s In-Booth Knowledge Forum at the 2012 ASM featured two exciting talks on MALDI-TOF Mass

Spectrometry by Dr. Melissa Miller from UNC School of Medicine, Chapel Hill and Dr. Christine Ginocchio from

Hofstra University North Shore-LIJ Health System School of Medicine, Lake Success, NY.

bioMér ieuxConnect ion August 2012

MALDI-TOFDrawsCrowdatASM2012

P A g E 2

Dr.Miller’stalkcenteredonthe“PowerandPromise”ofMALDI-TOFtechnologyforfutureuseinclinicalmicrobiology.ShedemonstratedthebioMérieuxVITEK®MS*system’sabilitytoconsolidatetheaccurateidentificationsofabreadthofdifferentorganismgroups.TheperformanceofthosestudiedrangedfromroutineGramnegativerodsandGrampositivecocci,variousgenera/speciesofYeastandnon-fermentingGramnegativerodsisolatedfromCysticFibrosispatients.

Dr.Ginocchio’spresentationfocusedonthe“PositiveImpactonResultsandWorkflow”oftheVITEKMS.Shesharedherexperienceswithanelegantworkflowaidedbythesystem’sPrepStation.ThePrepStation’sgraphicalsoftware,simplesample

acquisitionandidentificationresultreportingmaketheVITEKMSeasytouse.HertalkalsofocusedonimpressiveresultsgeneratedacrossGramnegativeandGrampositiveorganismsincludingseveralanaerobicspecies.

TheinterestinVITEKMSMALDI-TOFtechnologywasveryhighasevidencedbythe“standing-room-only”settingforbothtalkswithattendeesspillingintotheperipheryofthepresentationarea.Bothpresentationscanbeviewedonlineatwww.biomerieux-usa.com/education>Symposia>2012ASM.

*Researchuseonly.Notforclinicaluse.

P A g E 3

C O M I N g S O O N :

NewVITEK®2GNASTcardswillbeavailableOctober 1, 2012!


WearepleasedtoannouncethatthenewformulationofPiperacillin/Tazobactam(Pip/Tazo)hasbeengrantedmarketclearancebytheFDA,andwillbeofferedonnewGramnegativeantibioticsusceptibilitytest-ing(GNAST)cardsforboththeVITEK®2andVITEK®2Compactsystems.ThenewGNASTcardswillalsoofferre-developedImipenemwithimprovedperformanceandnewMICcallingranges.

ThenewVITEK2GNASTcardswillrequiresoftwareversion5.04.ThismandatorysoftwareupdateshouldonlybeappliedtoVITEK2systemsinstalledwithVITEK2SystemsSoftware5.01.TheVITEK25.04productupdateincludes:

• Piperacillin/Tazobactamwithnewformulation- MICcallingrange≤4-≥128

• Imipenemwithexpandedcallingrange - NewMICcallingrange≤0.25-≥16

Amulti-centerevaluationofthenewPip/TazoforuseonthenewGNASTcardsforVITEK2andVITEK2Compactsystemswasperformedusingbothclinicalandchallengeisolates.PerformancewasstrongcomparedtoastandardbrothmicrodilutionmethodusingCLSIbreakpoints,showing94.8%

essentialagreement,and94.3%categoricalagreement.

TheAST ConfiguratorisaninteractivetoolthatwillhelpyouandyourclinicianschoosewhichnewGNASTcardisrightforyourinstitution.Simplyplugintheantibioticsthatmeetyourformularyneeds,andtheASTConfiguratortoolwillrecommendthemostlogicalVITEK2cardforyou.Pleasevisitthelinkbelow,andbeginusingtheASTConfiguratortooltoday!

www.totalast.com

VITEK®2GramNegativeSusceptibilityTestCards


P A g E 4

A vA I L A B L e O C TO B e r 1 , 2 0 1 2

SoftwareRequirements:VersionPC5.04ForelectronicmenuandthemostcurrentVITEK2information,pleasevisitwww.biomerieux-usa.com/vitek2Pleasenote:Yourcustomernumberisneededtoaccessthissite.

AST-gN66 (413398)

AmpicillinAmpicillin/Sulbactam

CefazolinCefepimeCefoxitin

CeftazidimeCeftriaxone

CiprofloxacinErtapenem

ESBLConfirmationTestGentamicin

Imipenem(newformula)Levofloxacin

NitrofurantoinPiperacillin/Tazobactam

TobramycinTrimethoprim/Sulfamethoxazole

AST-gN70 (413401)

AmikacinAmpicillin

Ampicillin/SulbactamAztreonamCefazolinCefepime

CeftriaxoneCiprofloxacinErtapenem

ESBLConfirmationTestGentamicinMeropenemNitrofurantoin

Piperacillin/TazobactamTigecyclineTobramycin

Trimethoprim/Sulfamethoxazole

AST-gN67 (413399)

AmikacinAmpicillin

Ampicillin/SulbactamCefazolinCefepime







AST-gN71 (413402)

AmikacinAmpicillin




Imipenem(newformula)MeropenemMoxifloxacin

NitrofurantoinTigecyclineTobramycin


AST-gN68 (413431)

AmikacinAmpicillin



CiprofloxacinDoripenemErtapenem

ESBLConfirmationTestGentamicinLevofloxacin



AST-gN72 (413403)

Amoxicillin/ClavulanicAcidAmpicillinCefalotinCefazolinCefepimeCefoxitin

CefpodoximeCeftazidimeCeftriaxoneCefuroximeCiprofloxacinGentamicinLevofloxacin


TetracyclineTobramycin


AST-gN69 (413400)

Amoxicillin/ClavulanicAcidAmpicillin








AST-gN73 (413404)

AmikacinAmpicillin

Ampicillin/SulbactamCefazolinCefepimeCefoxitin


CiprofloxacinESBLConfirmationTest

GentamicinLevofloxacinMeropenemNitrofurantoin

Piperacillin/TazobactamTobramycin


AST-XN06 (413944)*

AmikacinAztreonamCefalotin

CefotaximeCefotetanCefoxitin

CefpodoximeCeftizoximeCefuroximeDoripenemMeropenemMoxiflaxacinNalidixicAcidNorfloxacinPiperacillinTetracyclineTicarcillin

Ticarcillin/ClavulanicAcidTigecycline

AST-gN74 (413941)

AmikacinAmpicillin/Sulbactam

AztreonamCefazolinCefepimeCefoxitin

CeftazidimeCeftriaxoneErtapenemGentamicinLevofloxacinMeropenemNitrofurantoin

Piperacillin/TazobactamTetracyclineTigecyclineTobramycin


*LinkswithAST-GN69

P A g E 5


AST-gN75 (413432)

AmikacinAmpicillin




ESBLConfirmationTestGentamicinLevofloxacinMeropenemNitrofurantoin

PiperacillinTobramycin


AST-gN80 (413437)


AztreonamCefazolinCefepime

CeftazidimeCeftriaxoneErtapenem

ESBLConfirmationTestGentamicinLevofloxacinMeropenemNitrofurantoin



AST-gN85 (413874)

AmikacinAmpicillin


CefpodoximeCeftazidimeCeftriaxone

CiprofloxacinDoripenemErtapenemGentamicinMeropenemNitrofurantoin

Piperacillin/TazobactamTigecycline


AST-gN76 (413433)

AmikacinAmpicillinCefazolinCefepimeCefoxitin






TigecyclineTrimethoprim/Sulfamethoxazole

AST-gN81 (413438)

AmikacinAmoxicillin/ClavulanicAcid

AmpicillinCefazolinCefepimeCefoxitin


CiprofloxacinErtapenemGentamicinLevofloxacinMeropenemNitrofurantoin

Piperacillin/TazobactamTobramycinTetracycline


AST-gN86 (413942)

Amoxicillin/ClavulanicAcidAmpicillin


CeftazidimeCeftriaxoneCefuroximeCiprofloxacinErtapenem



NitrofurantoinTetracyclineTobramycin


AST-gN77 (413434)


AmpicillinAztreonamCefazolinCefepimeCefoxitin

CeftriaxoneCiprofloxacinErtapenemGentamicin



TigecyclineTobramycin


AST-gN82 (413439)




CiprofloxacinErtapenemGentamicin

Imipenem(newformula)LevofloxacinMeropenem



AST-gN87 (413943)


CefazolinCefepime



ESBLConfirmationTestImipenem(newformula)

LevofloxacinMeropenemNitrofurantoin



AST-gN78 (413435)

AmikacinAmpicillin




ESBLConfirmationTestImipenem(newformula)

MoxifloxacinNitrofurantoin

Piperacillin/TazobactamTigecycline


AST-gN83 (413440)




CefotaximeCefoxitin

CeftazidimeCeftriaxoneCefuroximeCiprofloxacinGentamicinMeropenemNitrofurantoin

Piperacillin/TazobactamTrimethoprim/Sulfamethoxazole

AST-gN89 (414367)

Amoxicillin/ClavulanicAcidAmpicillinAztreonamCefalotinCefazolinCefipime

CeftazidimeCeftriaxoneErtapenemGentamicinLevofloxacinMeropenemNitrofurantoin

Piperacillin/TazobactamTetracyclineTobramycin


AST-gN79 (413436)

AmikacinAmpicillin




ESBLConfirmationTestGentamicinMeropenemNitrofurantoin



AST-gN84 (413410)

Amoxicillin/ClavulanicAcidAmpicillinAztreonamCefazolinCefepime



Imipenem(newformula)LevofloxacinMeropenemNitrofurantoinTetracycline

Piperacillin/TazobactamTrimethoprim/Sulfamethoxazole

P A g E 6


Agar-BasedTestingbyanMICMethodCriticaltotheManagementofCysticFibrosisPatients

Treatmentinvolvesantibiotictherapytoinhibittheprogressionoftheseinfections.PatientstypicallyvisittheirCFcliniceverythreemonths,duringwhichtheantibioticsusceptibilityoftheirlungfloraisassessedandtheirantibiotictherapyre-evaluated.BecauseoftheuniquepropertiesofbacteriagrowingintheCFlung,evaluationoftheirantibioticsusceptibilityrequiresspecialprotocolsandtechniquesinsteadofthehigh-throughputautomatedmeth-odsemployedformostsamplesinhospitalmicrobiologylaboratories.

bioMérieuxspokewithDr. Blake Buchan,AssociateDirectorofMicrobiologyatDynacareLaboratories,Milwaukee,WIandInstructorofPathologyattheMedicalCollegeofWiscon-sinaboutthespecificissuessurroundingantibioticsusceptibilitytestingforCFisolates.

bioMérieux:DosomelabsspecializeinCFsampletesting?Ifso,why?Isittheequipment,location,labstaffspecialty?

Dr. Buchan:Thereareanumberofhospitals/labsthatareaccreditedbytheCFFounda-tion.ThesecentersarereviewedperiodicallytobesurethattheyareadheringtoCFFoun-dationguidelinesforpatientmanagementandmonitoring/treatmentofCF.ThesecenterstypicallyhaveCFspecialistsonstaffwhoseepatientsbutmayalsohavefacultyinvolvedinactiveresearchprogramsrelatingtoCFandCFmicrobiology.BothChildren’sHospitalofWisconsinandFroedtertHospital/MedicalCollegeofWisconsinareCFFoundationaccreditedcenters.

bioMérieux:ExplaintheproblemsthatarisewhenrelyingonautomatedASTtotestCFsamples.

Dr. Buchan:AutomatedASTsystemsareaneffectivemethodtodetermineMICsformanyofthepathogensencounteredintheclinicallab.IntervalmonitoringofmicrowellculturestodetectgrowthinthepresenceofvariousconcentrationsofantibioticcanreducethetimeittakestoestablishanMIC.However,thesesystemsarenotidealforassessingMICofisolatesfromtheCFlung.

Growthcharacteristicsoftheseisolatescanbequiteabnormalandverydifferentfrom“wildtype”strains.Recurrent/continualexposuretoantibioticscanleadtomutationsthatsignificantlyreducethegrowthrateofsomeofthebacteriapres-ent.Agreatexampleisthesmallcolonyvariants(SCVs)ofS.aureusthatariseinresponsetosulfamethoxazole/trimethoprimtherapy.SimilarreductionsingrowthratecanbeseeninP.aeruginosa,resultingfrommutationsthatconferresistance,

The cause of cystic fibrosis (CF) is a mutation to the cystic fibrosis

transmembrane conductance regulator (CFTr) gene, which is a common

recessive mutation among those of european descent. In individuals that

are homozygous, the mutation disrupts ion transport in the epithelial

cells lining the passageways of the lungs, digestive system, pancreas,

and many other organs. In the lungs, this leads to the buildup of a thick

mucus that fosters chronic infections.

orastheresultofgrowthasabiofilm.Au-tomatedASTsystemscanbeunder-callingofresistanceinthesestrains.ThisoccursbecausenogrowthisdetectablewithinthesamplingtimeframeestablishedintheASTsystemalgorithm.

Anothermajordifferencebetweeniso-latesobtainedfromtheCFlungandthoseobtainedfromotherinfectionsismodalityofgrowth,specificallygrowthasabiofilm.P.aeruginosainparticularwilltendtogrowasabiofilmintheCFlungwhichleadstowholesalechangesingeneexpressionincludingtheoverproductionofalginate.Whenisolatedinculturethesestrainsgrowasextremelymucoidcolonies.Thiscancausetwoproblems.First,thereisageneralreductioningrowthrateasthebacteriaexpendadisproportionalamountofenergyproducingallofthisalginate.Second,thecoloniesarecomposedoffarlessviablebacteria.Thatis,mostofthemassofthecolonyisalginate.WhenmakingstandarddilutionsoftheseisolatesforautomatedAST,youmaysignificantlyunderestimatetheactualCFU/mlpresentandtherebysignificantlyunderinoculatetheautomatedAST.Similartotheeffectofslowgrowingbacteria,theneteffectcanbeunder-callingofresistance.

bioMérieux:TheCysticFibrosisFounda-tionhasrecommendedusingagar-based

methodssuchasdisk-diffusionorEtest®.Whatarethebenefitstosuchmethodsoverthealternatives?

Dr. Buchan:Severalthingscometomind.Agar-basedmethodsofASTarebasedonend-pointobservations(beit18or24hours)ratherthanalgorithmsaimedatdeterminingifgrowthoccurredoverconsecutivetimeintervals.Itpreventscall-ing“susceptible”tooearlyandpotentiallymissinggrowthofslowergrowingbacteriaatlatertimepoints.

Anotheradvantageofagar-basedmethodspertainingspecificallytoisolatesfromCFpatientsisthegrowthmodalityonsolidmediumversusinbrothmicrowells.Growthonsolidmediumbettermimicstheenviron-mentoftheCFlung.Specifically,itallowsthegrowthofP.aeruginosaasabiofilm.Forvariousreasonsrangingfromphysicalproperties(reduceddiffusionofantibiotics)tometabolicproperties(generallyreducedrateofmetabolisminabiofilm),isolatesgrowingasabiofilmaremoreresistanttoantibioticsthanfree-livingor“planktonic”counterparts.ItmakessensetoassessthesusceptibilityofisolatesgrowingasabiofilmratherthanplanktonicallyinbrothsincethisistheformthatantibiotictherapymustbeeffectiveattreatingduringCFexacerbations.

AnothercharacteristicofP.aeruginosagrowinginbiofilmsistheevolutionofdifferentcolonymorphotypesandatrendtowardincreasedantibioticresistance.Oneofthemanifestationsofthiscanbe“het-eroresistance”.Thisoccurswhenthereisasubpopulationwithinaculturethathasincreasedresistancetoadrugduetoarecentmutationorreducedgrowthrate.ThisphenomenonismorecommoninGram-positiveorganismsbutisalsoseeninP.aeruginosaisolatedfromCFlungs.Onsolidmedia,heteroresistanceisobservedastinyisolatedcolonieswithinthediskorEteststripzoneofinhibition.Whensubcultured,thesecolonieswilloftendemonstrateele-vatedresistanceascomparedtotheparentstrain.Strainsdisplayingheteroresistancecouldberefractorytotherapyduetotheresistantsubpopulation.Withbroth-basedtestingthisresistantsubpopulationiseasytooverlooksinceitisonlyaminorconstitu-entofthebacterialpopulationandmaynotachievesufficientgrowthtobedetectedbyautomatedASTsystems.

Agar-baseddiskorEtestmethodsalsoallowthelabtobenimbleinresponsetochangesinhospitalformulary,newantibiot-ics,andchangingbreakpoints.RevisionofbreakpointscanbeamajorproblemforautomatedASTpanelsthattypicallyhavea

narrowrangeofdilutionsforeachantibi-otictomaximizethenumberofantibioticsthatcanbeincludedonasinglepanel.Ifbreakpointsarerevisedoutofthisrange,manufacturersneedtodevelopnewpanelsthatneedtobeevaluatedbytheFDAthroughclinicaltrials.Thiscandramaticallyslowtimetomarketanddelayadoptionofnewbreakpointsbyclinicallaboratories.Incontrast,diskdiffusionmethodandEtestarecapableofmuchwidergradientsofantibioticconcentrationallowingflexibilityinadjustingtochangingbreakpoints.

TO READ THE FULL INTERVIEW WITH DR. BUCHAN, please visit Connection Online, www.biomerieux-usa.com/connection

EarlyinCF,theisolatesarerelativelysusceptibletomanyantibiotics.Asresistanceincreases,MICdatacanbeusedtochangeoroptimizetherapy.

P A g E 7


BlakeW.Buchan,PhD,isInstructorofPathol-ogyattheMedicalCollegeofWisconsinandAssociateDirectorofMicrobiologyatDynacareLaboratories,Milwaukee,WI.HisinterestsincludeMALDI-TOFMS,PCR,andMicroarray-baseddiagnosticsforthedetectionofbacterial,viralandfungalpathogens,aswellasdetectionofthoseetiologiesdirectlyfromspecimensandtheuseofnoveltechniquesforantimicrobialsusceptibilitytesting.

CO

easyMAG®

Sputum

Isola

Color Gram

chromID™

Smart IncubatorSystem VITEK® 2

VITEK MS™

Myla®

VILINK®

Etest®

VITEK® 2 AES™

Detection Collection Sample Prep Culture Identification Sensitivity Interpretation Reporting Decision

EasyQ®/ARGENE

The Microbiology Pathway:from Collection to Care

CollectionThe Pathway

ContaminationWorkflow issues

Sample Prep

Avoid rework

Culture

Quality

Identification

Time and Coverage

Sensitivity

Time and Coverage

Interpretation

Intelligence

Reporting

Efficiency

Care

Confidence

FormoreinformationaboutEtest®forCFisolateAST,contactyourlocalsalesrepresentativeorvisitwww.biomerieux-usa.com/Etest

P A g E 8

BabyBoomersandSepsis:TheLoomingCrisisandtheToolstoAvertIt

Those65yearsofageandolderaccountforone-eighthofthetotalU.S.population,yetthisgroupaccountsfortwo-thirdsofallsepsiscases—andtheBabyBoomergenera-tionisnowincreasingthispatientdemo-graphicexponentially.Fortunatelytherearetoolssuchasprocalcitonin(PCT)testing,alongwithEarlyGoalDirectedTherapy(EGDT)forsepsisthathospitalscanrelyontosavelives.Thechallengeisgettingmorehospitalstousethesetools.

“ThefirstU.S.BabyBoomerswillturn65in2011,inauguratingarapidincreaseintheolderpopulationduringthe2010to2030period.Theolderpopulationin2030ispro-jectedtobedoublethatof2000,growingfrom35millionto72million,”accordingtoastudypublishedbytheU.S.Dept.ofCensusin2005titled“65+intheUnitedStates:CurrentPopulationReportsSpecialStudy.”

Datapresentedatthe2011CHESTcon-ferencedemonstratetheimpactsepsisishavingonpatients65andolderwhohaveanunderlyingmedicalconditionthatleadstoimmunosuppression.ThestudybyFernandezetal.concludedthatelderlypatientswithseveresepsisandimmunosup-pression,lungmetastasis,neutropenia,andcisplatintherapyhavea30-daymortalityratemuchhigherthansepsispatientsinthisagegroupwhodonothavetheseconditionsortherapies.Theseimmunosuppressed

patientsrepresentedextremelycommon(andgrowing)diseasestatesandtherapiesincludingcancerandsteroidtherapy.

Twostepscouldbetakenimmediatelytohelppreventthisloomingcrisis:

1. Requirehospitalstomakesepsisacoremeasureandpushforstandardizingprotocolsandreportingmortalityrates.Untilthathappens,sepsiswillbeoneofhundredsofproblemscompetingforscarceresourcesandprioritystatus.

2. Adoptscreeningtestsforsepsis,suchasPCT,asstandardbloodtestsforallelderlypatientswhoareadmittedtothehospital.Asnotedearlier,thispopulationisatincreasedrisk,andmaynotalwaysdisplaytheclassicSIRS(systemicinflam-matoryresponsesyndrome)criteriabecauseofcomorbidconditionsandconcomitantmedications.

PCTisoneofthemoreusefulbiomarkersforsepsis.Itwillrisewellbeforelactatelevels,

allowingearlytherapypriortothedevelop-mentofshockforsepticpatients.PCTcouldbecomeanothermarkertobringpatientsintoEGDTbesidesbloodpressureandlactatelevels.PCTalsoprovidesanearlierdiagnosisofinfectioninpatientsalreadyinthehospitalforotherreasons.Earlyappropri-ateantibioticsmaybethemostimportanteffectorofmortalityinsepsis,andPCTwilloftenrisebeforeclinicaldiagnosisofinfec-tionismade,allowingforearlierinitiationofantimicrobials.PCTwillalsohelpdistinguishsepsisfromnon-sepsisSIRS.Andfinally,PCTcanassistindefiningthecauseofshockorlacticacidosisinunstablepatientsthatpres-entbutforwhomdiagnosisisstillunclear.PCTriseswithbacterialsepsis,butusuallydoesnotincasesofhypovolemic,cardio-genic,orobstructiveshock.

Forthetruthtobetold,wephysiciansarejustnotasgoodatdiagnosingsepsisaswethinkweare.Withoutadditionalbiomark-erslikelactateandPCT,doctorsattemptingtodiagnosesepsisatthebedsideareonlyabout70-80percentaccurate.Forsuchadeadly(buttreatable)condition,thissimplyisn’tgoodenough.Ibelievethatthroughmorewidespreaduseofprocalcitonin,95percentaccuracyisveryattainable.

The number of sepsis cases in the United States is increasing and, due to an aging population, an increase in underlying conditions that can cause immunosuppression and the growing problem of antibiotic resistance, the sepsis-vulnerable community is getting larger.

WithoutadditionalbiomarkerslikelactateandPCT,doctorsattemptingtodiagnosesepsisatthebedsideareonlyabout70-80%accurate.


MarkOltermann,M.D.,isdirectoroftheMedicalICUandViceChairmanoftheDepartmentofInternalMedicineatJohnPeterSmithHospital,a430-bedLevel1

traumacenterinFortWorth,Texas.Hemanagesfourfull-timeintensivistsatthehospital,whichishometothecountry’slargest

FamilyPracticeResidency.

Every 3-4 seconds someone dies of sepsis.

Join the fight against sepsis – World Sepsis Day September 13, 2012.

Formoreinformation,visitwww.world-sepsis-day.orgorwww.SepsisKnowFromDay1.com.

“MortalityofElderlyPatientsWithImmunosuppressionandSevereSepsis,”JuanFernandez,MD;AndrewShorr,MD;EricMortensen,MD;AntonioAnzueto,MDandMarcosRestrepo,MD,CHEST2011,abstract.

Procalcitonin,anewbiomarkerwithrapidresultsin20minutesforclearindicationsof:

• Systemicbacterialinfections• SevereSepsis• SepticShock

Severe Sepsis Strikes 750,000 Americans Every Year.*The first hour is critical – the first 24 hours can be decisive.Procalcitonin provides critical biomarker information that can helpincreasetheaccuracyofearlysepsisdiagnosis.

Learn more at: www.SepsisKnowFromDay1.com

VisitusatIDWeek2012,October17-21,inSanDiegoatBooth#421.

*AngusDC,Linde-ZwirbleWT,LidickerJ,etal.EpidemiologyofseveresepsisintheUnitedStates:Analysisofincidence,outcome,andassociatedcostsofcare.CritCareMed2001;29:1303-1310.

©2012BIOMÉRIEUX,INC.•BIOMÉRIEUX,THEBLUELOGOANDVIDASAREUSEDPENDINGAND/ORREGISTEREDTRADEMARKSBELONGINGTOBIOMÉRIEUXSAORONEOFITSSUBSIDIARIES.

Gold is the new blackNew BacT/ALERT® media

Taking a leap forward with Adsorbent Polymeric Beads (APB) media

Gold is the new blackNew BacT/ALERT® media

Taking a leap forward with Adsorbent Polymeric Beads (APB) media

• StreamlinedmethodforupdatingBacT/ALERT®3Dfirmware

• KeyboardnavigationontheEditDataRelationshipsscreens

• Electronicrecordoffirmwareupdatesandbarcodecustomizations

• ForSelectLinkconfigurationsonly:Time-to-DetectionresultincludedwhensendingpreliminaryresultstotheLaboratoryInformationSystem(LIS)

• Bottlereadingsrecalculatedintheeventofanalgorithmchangewhenidentifyinganonymouslyloadedbottles

Thefirmwareupdatehasanew“AlgorithmRecalculation”featurethatdecreasesthenumberoffalsepositivesduetoanonymouslyloadedbottles.Onceananonymouslyloadedbottleisscanned,anewmessageboxwillappear.

Whenbottlesareloadedanonymously,readingsareanalyzedusingthestandarddefaultalgorithm.WiththeB.40firmwareupdate,whenanonymousbottlesareidentified,thefirmwarewillre-analyzethebottlereadingsusingthealgorithmspecificforthatbottletype.

WhentheBacT/ALERT3DVersionB.40firmwarerecognizesthatthebottletypeusesanalgorithmotherthanthestandarddefaultalgorithm,analarmsoundsandaCode931operatormessageappearstoinformtheoperatorthatthetestresultwillberecalculated.

Newoperatormessageboxappearsonceanonymousbottleisscanned:

P A g E 1 1

B.40FirmwareUpgrade

C O M I N g S O O N :


bioMérieux will begin shipping out the latest firmware update for the BacT/ALerT® 3D system.

The following features are included in the BacT/ALerT 3D version B.40 firmware update:

Keep this article as a reminder of the Algorithm recalculation message.

B.40 Firmware upgrade

Old Algorithm

New Algorithm

Bottle ID

Coming Soon:

Beginning in March, bioMérieux will begin shipping out the latest firmware update for the BacT/ALERT® 3D system. The following features are included in the BacT/ALERT 3D Version B.40 firmware update:

streamlined method for updating BacT/ALERT® 3D firmwarekeyboard navigation on the Edit Data Relationships screenselectronic record of firmware updates and barcode customizationsfor SelectLink configurations only: Time-to-Detection result included when sending preliminary results to the Laboratory Information System (LIS)bottle readings recalculated in the event of an algorithm change when identifying anonymously loaded bottles

The firmware update has a new “Algorithm Recalculation” feature that decreases the number of false positives due to anonymously loaded bottles. Once an anonymously loaded bottle is scanned, a new message box will appear.

When bottles are loaded anonymously, readings are analyzed using the standard default algorithm. With the B.40 firmware update, when anonymous bottles are identified, the firmware will re-analyze the bottle readings using the algorithm specific for that bottle type.

When the BacT/ALERT® 3D Version B.40 firmware recognizes that the bottle type uses an algorithm other than the standard default algorithm, an alarm sounds and a Code 931 operator message appears to inform the operator that the test result will be recalculated.

New operator message box appears once anonymous bottle is scanned:

Keep this article as a reminder of the Algorithm Recalculation message.

B.40 Firmware upgrade

Old Algorithm

New Algorithm

Bottle ID

Coming Soon:

Beginning in March, bioMérieux will begin shipping out the latest firmware update for the BacT/ALERT® 3D system. The following features are included in the BacT/ALERT 3D Version B.40 firmware update:

streamlined method for updating BacT/ALERT® 3D firmwarekeyboard navigation on the Edit Data Relationships screenselectronic record of firmware updates and barcode customizationsfor SelectLink configurations only: Time-to-Detection result included when sending preliminary results to the Laboratory Information System (LIS)bottle readings recalculated in the event of an algorithm change when identifying anonymously loaded bottles

The firmware update has a new “Algorithm Recalculation” feature that decreases the number of false positives due to anonymously loaded bottles. Once an anonymously loaded bottle is scanned, a new message box will appear.

When bottles are loaded anonymously, readings are analyzed using the standard default algorithm. With the B.40 firmware update, when anonymous bottles are identified, the firmware will re-analyze the bottle readings using the algorithm specific for that bottle type.

When the BacT/ALERT® 3D Version B.40 firmware recognizes that the bottle type uses an algorithm other than the standard default algorithm, an alarm sounds and a Code 931 operator message appears to inform the operator that the test result will be recalculated.

New operator message box appears once anonymous bottle is scanned:

Keep this article as a reminder of the Algorithm Recalculation message.

2012 EVENTS CALeNDAr

bioMérieuxConnectionispublishedbybioMérieux,Inc.,100RodolpheStreet,Durham,NC27712.Pleasesendaddresscorrectionsandmailinglistadditionstoinfo.biomerieux@biomerieux.com.Forcustomerservice,calltollfree800-682-2666.Pleasevisitourwebsiteatwww.biomerieux-usa.com.Pleaseshareyourcommentsandsuggestionswithusthroughyourlocalaccountmanagerorbyemailingusattheaddressabove.Asalways,wethankyouforbeingabioMérieuxcustomer.

©2

012

BIO

MÉR

IEU

X,IN

C.T

HE

BLU

ELO

GO

,BAC

T/AL

ERT

,ETE

ST,A

ND

VIT

EK

ARE

REG

ISTE

RED

TR

ADEM

ARKS

OF

BIO

MÉR

IEU

X.P

RIN

TED

INU

SA.B

MX-

079-

12

100RodolpheStreetDurham,NorthCarolina27712

www.biomerieux-usa.com

ADDRESSSERVICEREQUESTED

Date Event and Location

AUG

Denver Signature event, Denver,CO,DenverAquariumBallroom

SepT

OCT

pSS Medical expo, Orlando,FLICAAC, SanFrancisco,CAIntermountain State Seminar (IMSS), JacksonHole,WYbioMérieux Sponsored Dinner at IMSS, JacksonHole,WY

American College emergency physicians (ACep), Denver,CO,Booth#636Northwest Lab Symposium, Portland,ORIDWeek/IDSA, SanDiego,CA,Booth#421Association for Molecular pathology, LongBeach,CA

30

5-79-1226-2926

8-1117-2017-2025-27

bioMérieux

Newsletter

Pip/Tazo: Back in the cards!

Documents

Transcript of Pip/Tazo: Back in the cards!